指南与共识精神分裂症与精神病性障碍

遵守NICE精神分裂症指南推荐的成本与健康影响

Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations.
指南 / 共识 · Br J Psychiatry · 2021-01-01

该研究采用离散事件模拟的全疾病模型,评估英国精神分裂症临床实践完全遵循NICE指南推荐相比现行实践的成本效果。结果显示完全依从可降低终生成本并改善质量调整生命年,其中及时提供氯氮平净货币效益最大。

要点

  • 完全依从NICE精神分裂症指南可降低终生成本并改善QALYs。
  • 及时提供氯氮平治疗难治性精神分裂症净货币效益最大。
  • 需加大投入改善指南依从性以提升患者生活质量并节约成本。

核心结论

  • 完全依从NICE精神分裂症指南推荐可降低终生成本并改善质量调整生命年。
  • 基于NICE每QALY获得2万至3万英镑的支付意愿阈值,及时提供氯氮平净货币效益最大。

研究设计与样本

  • 采用先前开发的精神分裂症全疾病模型,基于离散事件模拟方法评估依从NICE推荐的成本与健康影响。
  • 模拟三种改善依从性的情景:临床高危精神病患者普遍接受认知行为治疗、首发精神病患者普遍接受家庭干预、难治性精神分裂症患者及时接受氯氮平。

主要发现

  • 完全依从指南推荐可降低终生成本并改善质量调整生命年。
  • 及时提供氯氮平治疗难治性精神分裂症净货币效益最大,其次为临床高危精神病患者普遍接受认知行为治疗,再次为首发精神病患者普遍接受家庭干预。

关键数值与推荐

  • NICE支付意愿阈值为每获得一个QALY 2万至3万英镑。
  • 及时提供氯氮平治疗难治性精神分裂症净货币效益最大。

临床怎么用

  • 临床应优先推动难治性精神分裂症患者及时使用氯氮平。
  • 应推广临床高危精神病患者的认知行为治疗和首发精神病患者的家庭干预。
  • 需加大投入改善指南依从性以提升患者生活质量并实现潜在成本节约。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discrepancies between the National Institute for Health and Care Excellence (NICE) schizophrenia guideline recommendations and current clinical practice in the UK have been reported. AIMS: We aim to assess whether it is cost-effective to improve adherence to the NICE schizophrenia guideline recommendations, compared with current practice. METHOD: A previously developed whole-disease model for schizophrenia, using the discrete event simulation method, was adapted to assess the cost and health impacts of adherence to the NICE recommendations. Three scenarios to improve adherence to the clinical guidelines were modelled: universal provision of cognitive-behavioural therapy for patients at clinical high risk of psychosis, universal provision of family intervention for patients with first-episode psychosis and prompt provision of clozapine for patients with treatment-resistant schizophrenia. The primary outcomes were lifetime costs and quality-adjusted life-years gained. RESULTS: The results suggest full adherence to the guideline recommendations would decrease cost and improve quality-adjusted life-years. Based on the NICE willingness-to-pay threshold of £20 000-£30 000 per quality-adjusted life-year gained, prompt provision of clozapine for patients with treatment-resistant schizophrenia results in the greatest net monetary benefit, followed by universal provision of cognitive-behavioural therapy for patients at clinical high risk of psychosis, and universal provision of family intervention for patients with first-episode psychosis. CONCLUSIONS: Our results suggest that adherence to guideline recommendations would decrease cost and improve quality-adjusted life-years. Greater investment is needed to improve guideline adherence and therefore improve patient quality of life and realise potential cost savings.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jin H, Tappenden P, MacCabe JH, et al. Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. Br J Psychiatry. 2021. PMID: 33308329. doi:10.1192/bjp.2020.241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。